Compare Cytokinetics Inc (CYTK) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Cytokinetics Inc trades at $62.89 (market cap $8.62B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.62 (market cap $94.46M). The key difference: Cytokinetics Inc is far larger — about 91.3× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Cytokinetics Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days on average.
| CYTK | MSTZ | |
|---|---|---|
Market Cap | $8.62B | $94.46M |
Volume | 2,594,626 | 104,717,733 |
Sector | Health | Leveraged / Inverse |
52-Week High | $87.26 | $27.92 |
52-Week Low | $54.76 | $2.29 |
Typical Hold Time | 19 Days | 8 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
MSTZ trades at $2.58, down 3.01% with bearish technical signals from moving averages. The stock shows mixed momentum with neutral oscillators but negative moving average alignment. Key support sits at $2 with resistance at $3. Recent ETF coverage highlights the stock's inclusion in leveraged/inverse ETF discussions, though specific company fundamentals remain limited in available data.
Outlook remains cautious given technical weakness and limited fundamental visibility. The primary opportunity lies in potential technical rebounds from support levels, while risks include continued bearish momentum and lack of clear fundamental catalysts. Investors should await clearer financial metrics and earnings guidance for directional conviction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
